Ranibizumab and pegaptanib for the treatment of age-related macular degeneration

  • Technology appraisal guidance
  • TA155
  • Published: 
  • Last updated: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

The assessment report for this appraisal was prepared by Southampton Health Technology Assessment Centre, University of Southampton.

  • Colquitt JL et al. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation, November 2006.

The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Manufacturers, or sponsors, and professional or specialist and patient or carer groups were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

Manufacturers or sponsors:

  • Novartis (ranibizumab)

  • Pfizer (pegaptanib)

Professional or specialist and patient or carer groups:

  • Age Concern England

  • College of Optometrists

  • Counsel and Care for the Elderly

  • Department of Health

  • Macular Disease Society

  • Royal College of Nursing

  • Royal College of Ophthalmologists

  • Royal National Institute of Blind People

  • Welsh Assembly Government

Commentator organisations (without the right of appeal):

  • Medicines and Healthcare Products Regulatory Agency (MHRA)

  • NHS Quality Improvement Scotland

  • Novartis

  • Institute of Ophthalmology, University College London

  • NCCHTA

  • Southampton Health Technology Assessment Centre (SHTAC)

  • National Collaborating Centre Acute Care

The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer/sponsor consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on ranibizumab and pegaptanib by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Professor Simon Harding, Consultant Ophthalmologist, nominated by the Royal College of Ophthalmologists – clinical specialist.

  • Professor Andrew Lotery, Professor of Ophthalmology, nominated by the Royal National Institute of Blind People – clinical specialist.

  • Barbara McLaughlan, Eye Health Campaigns Manager, nominated by the Royal Institute of Blind People – patient expert.

  • Mrs Lydia Willie, nominated by the Royal Institute of Blind People – patient expert.